Baseline and post-treatment biomarkers of resistance to anti-PD-1 therapy in acral and mucosal melanoma: an observational study

BACKGROUND: Immunotherapies targeting programmed cell death-1 (PD-1) and its ligands have improved clinical outcomes for advanced melanoma. However, many tumors exhibit primary resistance or acquire secondary resistance after an initial positive response. The mechanisms of resistance are not well un...

Descripción completa

Detalles Bibliográficos
Autores principales: Shui, Irene M., Liu, Xiao Qiao, Zhao, Qing, Kim, Seung Tae, Sun, Yuan, Yearley, Jennifer H., Choudhury, Tasmiah, Webber, Andrea L., Krepler, Clemens, Cristescu, Razvan, Lee, Jeeyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9260847/
https://www.ncbi.nlm.nih.gov/pubmed/35793874
http://dx.doi.org/10.1136/jitc-2022-004879

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9260847/
https://www.ncbi.nlm.nih.gov/pubmed/35793874
http://dx.doi.org/10.1136/jitc-2022-004879

Ejemplares similares